drugset / Trial / NCT07086079

A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)

NCT07086079

Phase 1 Completed 12 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelBasic science

Summary

The goal of this study is to learn what happens to doravirine (DOR) and islatravir (ISL) in a healthy lactating female's body over time. Researchers want to learn if DOR and ISL are in breast milk.

Timeline

Start
2025-09-26
Primary completion
2025-12-08
Completion
2026-02-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Doravirine Small molecule Oral
Subject Islatravir Other / unclassified Oral

Indications

No indication recorded.